SCYNEXIS Inc (NASDAQ:SCYX) Director David C. Hastings purchased 11,834 shares of the business’s stock in a transaction dated Thursday, March 8th. The shares were purchased at an average price of $1.69 per share, with a total value of $19,999.46. Following the purchase, the director now directly owns 31,834 shares in the company, valued at approximately $53,799.46. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of SCYNEXIS Inc (NASDAQ SCYX) opened at $1.51 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.43 and a quick ratio of 4.43. SCYNEXIS Inc has a 1-year low of $1.35 and a 1-year high of $3.00.
Several research analysts have recently weighed in on SCYX shares. ValuEngine upgraded SCYNEXIS from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th. Zacks Investment Research downgraded SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $7.75.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in SCYNEXIS by 6.0% during the 2nd quarter. Vanguard Group Inc. now owns 868,394 shares of the company’s stock worth $1,554,000 after purchasing an additional 48,978 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in SCYNEXIS by 17.1% during the 3rd quarter. GSA Capital Partners LLP now owns 206,900 shares of the company’s stock worth $499,000 after purchasing an additional 30,200 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in SCYNEXIS during the 3rd quarter worth about $264,000. 30.11% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “SCYNEXIS Inc (NASDAQ:SCYX) Director Purchases $19,999.46 in Stock” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://ledgergazette.com/2018/03/20/scynexis-inc-scyx-director-david-c-hastings-acquires-11834-shares-of-stock.html.
SCYNEXIS Company Profile
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.